Amar­na rais­es €10M to push gene ther­a­py plat­form in­to clin­ic; Ed­i­tas Med­i­cine, AskBio join forces

Amar­na Ther­a­peu­tics  — de­vel­op­ing an SV40-based gene de­liv­ery vec­tor plat­form called SVac — has raised €10 mil­lion. The round was led by Swedish in­vest­ment com­pa­ny Flerie In­vest AB, along with con­tri­bu­tions from the Nether­lands En­ter­prise Agency and ex­ist­ing share­hold­er Pim Berg­er. The funds will be used to de­vel­op SVac and steer it in­to a first-in-man clin­i­cal study, ex­pect­ed to com­mence in the com­ing years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.